Baclofen for alcohol dependence in France: Incidence of treated patients and prescription patterns—A cohort study
Recently, baclofen has been widely promoted for treatment of alcohol dependence in France. Our aim was firstly to describe the incidence of patients newly treated with baclofen for alcohol dependence in France from 2007 to 2011, and secondly to describe baclofen prescription patterns and prescribers...
Saved in:
| Published in: | European neuropsychopharmacology Vol. 24; no. 2; pp. 192 - 199 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Netherlands
Elsevier B.V
01.02.2014
Elsevier |
| Subjects: | |
| ISSN: | 0924-977X, 1873-7862, 1873-7862 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Recently, baclofen has been widely promoted for treatment of alcohol dependence in France. Our aim was firstly to describe the incidence of patients newly treated with baclofen for alcohol dependence in France from 2007 to 2011, and secondly to describe baclofen prescription patterns and prescribers. A retrospective cohort study of patients newly treated with baclofen was conducted using the “Echantillon Généraliste des Bénéficiaires” database (EGB). Patients with a first dispensation of baclofen between 01/01/2007 and 31/12/2011, followed by a second in the next 120 days, were included. Patients were considered treated with baclofen for neurological conditions if at least one of the following conditions was found to be true: (1) presence of a neurological condition for which baclofen could be prescribed, (2) dispensation of dantrolene, another anti-spastic drug, or (3) hospitalization for a neurological condition for which baclofen could be prescribed. We assumed that all the remaining patients were treated for alcohol dependence. During the 5-year period, 676 patients were incident users. While the annual incidence rate of patients newly treated with baclofen for neurological conditions remained stable, the annual incidence rate of patients newly treated with baclofen for alcohol dependence increased by a factor of 2.9 between 2007 (0.09/1000 person-years) and 2011 (0.26/1000 person-years). In the alcohol dependence group, median duration of baclofen treatment was 143.5 [74.0; 377.0] days; median daily dose was 24.4 [14.8; 39.5] mg. This study demonstrated the rapidly increasing use of baclofen in France for treatment of alcohol dependence. |
|---|---|
| AbstractList | Recently, baclofen has been widely promoted for treatment of alcohol dependence in France. Our aim was firstly to describe the incidence of patients newly treated with baclofen for alcohol dependence in France from 2007 to 2011, and secondly to describe baclofen prescription patterns and prescribers. A retrospective cohort study of patients newly treated with baclofen was conducted using the “Echantillon Généraliste des Bénéficiaires” database (EGB). Patients with a first dispensation of baclofen between 01/01/2007 and 31/12/2011, followed by a second in the next 120 days, were included. Patients were considered treated with baclofen for neurological conditions if at least one of the following conditions was found to be true: (1) presence of a neurological condition for which baclofen could be prescribed, (2) dispensation of dantrolene, another anti-spastic drug, or (3) hospitalization for a neurological condition for which baclofen could be prescribed. We assumed that all the remaining patients were treated for alcohol dependence. During the 5-year period, 676 patients were incident users. While the annual incidence rate of patients newly treated with baclofen for neurological conditions remained stable, the annual incidence rate of patients newly treated with baclofen for alcohol dependence increased by a factor of 2.9 between 2007 (0.09/1000 person-years) and 2011 (0.26/1000 person-years). In the alcohol dependence group, median duration of baclofen treatment was 143.5 [74.0; 377.0] days; median daily dose was 24.4 [14.8; 39.5] mg. This study demonstrated the rapidly increasing use of baclofen in France for treatment of alcohol dependence. Abstract Recently, baclofen has been widely promoted for treatment of alcohol dependence in France. Our aim was firstly to describe the incidence of patients newly treated with baclofen for alcohol dependence in France from 2007 to 2011, and secondly to describe baclofen prescription patterns and prescribers. A retrospective cohort study of patients newly treated with baclofen was conducted using the “Echantillon Généraliste des Bénéficiaires” database (EGB). Patients with a first dispensation of baclofen between 01/01/2007 and 31/12/2011, followed by a second in the next 120 days, were included. Patients were considered treated with baclofen for neurological conditions if at least one of the following conditions was found to be true: (1) presence of a neurological condition for which baclofen could be prescribed, (2) dispensation of dantrolene, another anti-spastic drug, or (3) hospitalization for a neurological condition for which baclofen could be prescribed. We assumed that all the remaining patients were treated for alcohol dependence. During the 5-year period, 676 patients were incident users. While the annual incidence rate of patients newly treated with baclofen for neurological conditions remained stable, the annual incidence rate of patients newly treated with baclofen for alcohol dependence increased by a factor of 2.9 between 2007 (0.09/1000 person-years) and 2011 (0.26/1000 person-years). In the alcohol dependence group, median duration of baclofen treatment was 143.5 [74.0; 377.0] days; median daily dose was 24.4 [14.8; 39.5] mg. This study demonstrated the rapidly increasing use of baclofen in France for treatment of alcohol dependence. Recently, baclofen has been widely promoted for treatment of alcohol dependence in France. Our aim was firstly to describe the incidence of patients newly treated with baclofen for alcohol dependence in France from 2007 to 2011, and secondly to describe baclofen prescription patterns and prescribers. A retrospective cohort study of patients newly treated with baclofen was conducted using the "Echantillon Generaliste des Beneficiaires" database (EGB). Patients with a first dispensation of baclofen between 01/01/2007 and 31/12/2011, followed by a second in the next 120 days, were included. Patients were considered treated with baclofen for neurological conditions if at least one of the following conditions was found to be true: (1) presence of a neurological condition for which baclofen could be prescribed, (2) dispensation of dantrolene, another anti-spastic drug, or (3) hospitalization for a neurological condition for which baclofen could be prescribed. We assumed that all the remaining patients were treated for alcohol dependence. During the 5-year period, 676 patients were incident users. While the annual incidence rate of patients newly treated with baclofen for neurological conditions remained stable, the annual incidence rate of patients newly treated with baclofen for alcohol dependence increased by a factor of 2.9 between 2007 (0.09/1000 person-years) and 2011 (0.26/1000 person-years). In the alcohol dependence group, median duration of baclofen treatment was 143.5 [74.0; 377.0] days; median daily dose was 24.4 [14.8; 39.5] mg. This study demonstrated the rapidly increasing use of baclofen in France for treatment of alcohol dependence. Recently, baclofen has been widely promoted for treatment of alcohol dependence in France. Our aim was firstly to describe the incidence of patients newly treated with baclofen for alcohol dependence in France from 2007 to 2011, and secondly to describe baclofen prescription patterns and prescribers. A retrospective cohort study of patients newly treated with baclofen was conducted using the "Echantillon Généraliste des Bénéficiaires" database (EGB). Patients with a first dispensation of baclofen between 01/01/2007 and 31/12/2011, followed by a second in the next 120 days, were included. Patients were considered treated with baclofen for neurological conditions if at least one of the following conditions was found to be true: (1) presence of a neurological condition for which baclofen could be prescribed, (2) dispensation of dantrolene, another anti-spastic drug, or (3) hospitalization for a neurological condition for which baclofen could be prescribed. We assumed that all the remaining patients were treated for alcohol dependence. During the 5-year period, 676 patients were incident users. While the annual incidence rate of patients newly treated with baclofen for neurological conditions remained stable, the annual incidence rate of patients newly treated with baclofen for alcohol dependence increased by a factor of 2.9 between 2007 (0.09/1000 person-years) and 2011 (0.26/1000 person-years). In the alcohol dependence group, median duration of baclofen treatment was 143.5 [74.0; 377.0] days; median daily dose was 24.4 [14.8; 39.5] mg. This study demonstrated the rapidly increasing use of baclofen in France for treatment of alcohol dependence.Recently, baclofen has been widely promoted for treatment of alcohol dependence in France. Our aim was firstly to describe the incidence of patients newly treated with baclofen for alcohol dependence in France from 2007 to 2011, and secondly to describe baclofen prescription patterns and prescribers. A retrospective cohort study of patients newly treated with baclofen was conducted using the "Echantillon Généraliste des Bénéficiaires" database (EGB). Patients with a first dispensation of baclofen between 01/01/2007 and 31/12/2011, followed by a second in the next 120 days, were included. Patients were considered treated with baclofen for neurological conditions if at least one of the following conditions was found to be true: (1) presence of a neurological condition for which baclofen could be prescribed, (2) dispensation of dantrolene, another anti-spastic drug, or (3) hospitalization for a neurological condition for which baclofen could be prescribed. We assumed that all the remaining patients were treated for alcohol dependence. During the 5-year period, 676 patients were incident users. While the annual incidence rate of patients newly treated with baclofen for neurological conditions remained stable, the annual incidence rate of patients newly treated with baclofen for alcohol dependence increased by a factor of 2.9 between 2007 (0.09/1000 person-years) and 2011 (0.26/1000 person-years). In the alcohol dependence group, median duration of baclofen treatment was 143.5 [74.0; 377.0] days; median daily dose was 24.4 [14.8; 39.5] mg. This study demonstrated the rapidly increasing use of baclofen in France for treatment of alcohol dependence. |
| Author | Jouanjus, Émilie Oustric, Stéphane Lapeyre-Mestre, Maryse Dupouy, Julie Poutrain, Jean-Christophe Palmaro, Aurore Fournier, Jean-Pascal |
| Author_xml | – sequence: 1 givenname: Julie surname: Dupouy fullname: Dupouy, Julie organization: UMR1027 Inserm—Université Paul Sabatier Toulouse III, Toulouse, France – sequence: 2 givenname: Jean-Pascal surname: Fournier fullname: Fournier, Jean-Pascal organization: UMR1027 Inserm—Université Paul Sabatier Toulouse III, Toulouse, France – sequence: 3 givenname: Émilie surname: Jouanjus fullname: Jouanjus, Émilie organization: UMR1027 Inserm—Université Paul Sabatier Toulouse III, Toulouse, France – sequence: 4 givenname: Aurore surname: Palmaro fullname: Palmaro, Aurore organization: UMR1027 Inserm—Université Paul Sabatier Toulouse III, Toulouse, France – sequence: 5 givenname: Jean-Christophe surname: Poutrain fullname: Poutrain, Jean-Christophe organization: Département Universitaire de Médecine Générale, Faculté de Médecine, Université Paul Sabatier Toulouse III, Toulouse, France – sequence: 6 givenname: Stéphane surname: Oustric fullname: Oustric, Stéphane organization: Département Universitaire de Médecine Générale, Faculté de Médecine, Université Paul Sabatier Toulouse III, Toulouse, France – sequence: 7 givenname: Maryse surname: Lapeyre-Mestre fullname: Lapeyre-Mestre, Maryse email: maryse.lapeyre-mestre@univ-tlse3.fr organization: UMR1027 Inserm—Université Paul Sabatier Toulouse III, Toulouse, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24139234$$D View this record in MEDLINE/PubMed https://hal.science/hal-03526189$$DView record in HAL |
| BookMark | eNqNkktuFDEQhi0URCaBK4CXsJjBr34YCdAQERJpJBaAxM5yu8uKhx57sN2RZschcsKcBDeTZBEJJRs_yn99VarfR-jABw8IvaJkQQmt364XMMYSKsuCEcoXRC4IaZ-gGW0bPm_amh2gGZFMzGXT_DxERymtCaEV5_IZOmSCcsm4mKH0SZshWPDYhoj1YMJFGHAPW_A9eAPYeXwadTm9w-feuH0wWJwj6Aw93urswOeEtS-XCMlEt80u-OklQ_Tp-s_VEk_cmHHKY797jp5aPSR4cbMfox-nn7-fnM1XX7-cnyxXc1MJmefSmpo1rdWsrlhdC15ZApZzIq2sDKkYMbSibQ9tXXXCNn3X1bruLLd125uu48fozZ57oQe1jW6j404F7dTZcqWmGOEFTFt5SYv29V67jeH3CCmrjUsGhkF7CGNSpVLdCNFw_rBUSMEJb0lbpC9vpGO3gf6uidv5F8H7vcDEkFIEq4zLehpfjtoNihI1-a3W6s5vNfmtiFTkX4HmXv5tiYczl_tMKA5cOogqGTeZ27sIJqs-uEcwPtxjmMF5Z_TwC3aQ1mGMvhisqEpMEfVt-o_Td6ScENaIqgA-_h_wqBb-AmeE9s0 |
| CitedBy_id | crossref_primary_10_1016_j_encep_2016_04_001 crossref_primary_10_1007_s41669_017_0050_3 crossref_primary_10_1016_j_revmed_2014_11_009 crossref_primary_10_1016_j_psym_2014_02_003 crossref_primary_10_1111_cns_12489 crossref_primary_10_1111_apt_13965 crossref_primary_10_1136_bcr_2016_217506 crossref_primary_10_1016_j_euroneuro_2015_07_006 crossref_primary_10_1007_s00228_014_1794_7 crossref_primary_10_1016_j_acvd_2016_01_012 crossref_primary_10_1016_j_alcohol_2025_03_002 crossref_primary_10_1093_alcalc_agx072 crossref_primary_10_1002_pds_4635 crossref_primary_10_1002_bmc_3936 crossref_primary_10_2515_therapie_2014056 crossref_primary_10_1016_j_drugalcdep_2016_02_035 crossref_primary_10_1111_fcp_12339 crossref_primary_10_2515_therapie_2015027 crossref_primary_10_1016_j_therap_2018_09_078 crossref_primary_10_1371_journal_pone_0098062 crossref_primary_10_4103_jrptps_JRPTPS_15_20 crossref_primary_10_2515_therapie_2015009 crossref_primary_10_3389_fpsyt_2016_00068 crossref_primary_10_1080_14740338_2017_1270939 crossref_primary_10_1016_j_therap_2019_06_002 crossref_primary_10_1007_s10557_015_6572_y crossref_primary_10_1007_s11096_015_0074_7 crossref_primary_10_1016_j_euroneuro_2015_05_008 crossref_primary_10_1517_14740338_2016_1168397 crossref_primary_10_1080_15563650_2017_1284330 crossref_primary_10_1016_j_euroneuro_2017_08_434 crossref_primary_10_1093_alcalc_agw011 crossref_primary_10_2515_therapie_2015011 crossref_primary_10_1007_s40263_014_0179_x |
| Cites_doi | 10.1186/1741-7015-9-119 10.1016/j.euroneuro.2011.07.018 10.1093/alcalc/ags060 10.1093/alcalc/agh130 10.1002/pds.1717 10.3389/fpsyt.2012.00103 10.1016/j.jsat.2008.08.006 10.1111/j.1530-0277.2003.tb02722.x 10.1007/BF03033315 10.1111/j.1742-6723.2006.00805.x 10.1016/S0376-8716(02)00333-2 10.2165/11597320-000000000-00000 10.1002/ana.410170202 10.1007/s00125-011-2429-5 10.1093/alcalc/37.3.261 10.1111/j.1530-0277.2010.01273.x 10.1002/pds.3213 10.1097/JCP.0b013e3181fb7b97 10.1016/S0140-6736(07)61814-5 10.1177/0091270010385936 10.2515/therapie/2010073 10.1093/alcalc/agr017 10.1016/j.clinre.2011.01.019 10.1007/s00228-011-1077-5 10.1016/j.euroneuro.2012.07.010 10.1002/14651858.CD008502.pub3 10.1111/j.1749-6632.2011.06298.x 10.1111/j.1360-0443.2011.03752.x 10.1016/j.respe.2011.03.059 10.1097/00002826-199208000-00002 10.1016/j.respe.2010.04.005 10.1002/pds.1933 10.1111/j.1472-8206.2010.00882.x 10.1093/alcalc/agr131 10.1212/WNL.41.11.1829 10.1093/alcalc/37.5.504 10.1111/j.1530-0277.2008.00805.x 10.1002/jhm.928 10.1016/j.amjmed.2005.08.042 10.1089/jwh.2009.1505 10.3109/00048674.2010.524622 |
| ContentType | Journal Article |
| Copyright | 2013 Elsevier B.V. and ECNP Elsevier B.V. and ECNP 2013 Elsevier B.V. and ECNP. All rights reserved. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: 2013 Elsevier B.V. and ECNP – notice: Elsevier B.V. and ECNP – notice: 2013 Elsevier B.V. and ECNP. All rights reserved. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7TK 1XC |
| DOI | 10.1016/j.euroneuro.2013.09.008 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Neurosciences Abstracts Hyper Article en Ligne (HAL) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Neurosciences Abstracts |
| DatabaseTitleList | Neurosciences Abstracts MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-7862 |
| EndPage | 199 |
| ExternalDocumentID | oai:HAL:hal-03526189v1 24139234 10_1016_j_euroneuro_2013_09_008 S0924977X13002745 1_s2_0_S0924977X13002745 |
| Genre | Journal Article |
| GeographicLocations | France Europe |
| GeographicLocations_xml | – name: Europe – name: France |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29G 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM 9JO AABNK AADFP AAEDT AAEDW AAGJA AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABFRF ABIVO ABJNI ABMAC ABMZM ABOYX ABWVN ABXDB ABZDS ACDAQ ACGFO ACGFS ACIEU ACIUM ACLOT ACRLP ACRPL ACVFH ACXNI ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRLJ AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDW HMK HMO HMQ HMT HVGLF HZ~ IHE J1W KOM LX8 M29 M2V M34 M41 MO0 MOBAO N9A O-L O9- OAUVE OGGZJ OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNS SPCBC SPT SSB SSH SSN SSP SSY SSZ T5K UNMZH WUQ XPP Z5R ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW RIG AADPK AAIAV AATCM ABLVK ABYKQ AFYLN AJBFU LCYCR 9DU AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8 7TK 1XC |
| ID | FETCH-LOGICAL-c549t-9fc6278fa265266435f0ef3309f95c0520c1518de865b4f7dbb6a6bf3f68dcbb3 |
| ISICitedReferencesCount | 41 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000331680100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0924-977X 1873-7862 |
| IngestDate | Sat Oct 25 06:41:03 EDT 2025 Sun Sep 28 08:54:22 EDT 2025 Sun Sep 28 08:19:44 EDT 2025 Mon Jul 21 06:02:37 EDT 2025 Tue Nov 18 22:35:04 EST 2025 Sat Nov 29 02:31:20 EST 2025 Fri Feb 23 02:26:23 EST 2024 Sun Feb 23 10:19:03 EST 2025 Tue Oct 14 19:34:42 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Addictive behavior Alcoholism General practitioners Baclofen Cohort studies Incidence |
| Language | English |
| License | 2013 Elsevier B.V. and ECNP. All rights reserved. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c549t-9fc6278fa265266435f0ef3309f95c0520c1518de865b4f7dbb6a6bf3f68dcbb3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| ORCID | 0000-0002-3510-2475 0000-0001-7801-286X 0000-0002-5660-9224 0000-0002-9971-0672 |
| PMID | 24139234 |
| PQID | 1494303808 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | hal_primary_oai_HAL_hal_03526189v1 proquest_miscellaneous_1516744733 proquest_miscellaneous_1494303808 pubmed_primary_24139234 crossref_citationtrail_10_1016_j_euroneuro_2013_09_008 crossref_primary_10_1016_j_euroneuro_2013_09_008 elsevier_sciencedirect_doi_10_1016_j_euroneuro_2013_09_008 elsevier_clinicalkeyesjournals_1_s2_0_S0924977X13002745 elsevier_clinicalkey_doi_10_1016_j_euroneuro_2013_09_008 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-02-01 |
| PublicationDateYYYYMMDD | 2014-02-01 |
| PublicationDate_xml | – month: 02 year: 2014 text: 2014-02-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | European neuropsychopharmacology |
| PublicationTitleAlternate | Eur Neuropsychopharmacol |
| PublicationYear | 2014 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Davidoff (bib18) 1985; 17 Dore, Lo, Juckes, Bezyan, Latt (bib20) 2011; 46 Malet, Reynaud, Llorca, Chakroun, Blanc, Falissard (bib33) 2009; 36 Effertz, Mann (bib21) 2013; 23 Beck, Guignard, Obradovic, Gautier, Karila (bib7) 2011; 59 Macaigne, Champagnon, Harnois, Cheiab, Chayette (bib31) 2011; 35 Addolorato, Leggio, Ferrulli, Cardone, Vonghia, Mirijello, Abenavoli, D′Angelo, Caputo, Zambon, Haber, Gasbarrini (bib4) 2007; 370 Rolland, Bordet, Cottencin (bib38) 2012; 107 Noize, Bazin, Dufouil, Lechevallier-Michel, Ancelin, Dartigues, Tzourio, Moore, Fourrier-Réglat (bib36) 2009; 18 Saddichha, Jayaram, Manjunatha, Benegal (bib41) 2011; 51 Garbutt, Kampov-Polevoy, Gallop, Kalka-Juhl, Flannery (bib25) 2010; 34 Braillon (bib10) 2012; 47 Fournier, Zureik (bib23) 2012; 21 Ameisen (bib5) 2005; 40 Addolorato, Caputo, Capristo, Domenicali, Bernardi, Janiri, Agabio, Colombo, Gessa, Gasbarrini (bib1) 2002; 37 Wittchen, Jacobi, Rehm, Gustavsson, Svensson, Jönsson, Olesen, Allgulander, Alonso, Faravelli, Fratiglioni, Jennum, Lieb, Maercker, van Os, Preisig, Salvador-Carulla, Simon, Steinhausen (bib47) 2011; 21 Colombo, Serra, Brunetti, Vacca, Carai, Gessa (bib16) 2003; 70 . ClinicalTrials.gov-b. Efficacy and Safety of Baclofen for Maintenance of Abstinence in Alcohol Dependent Patients. Malet, Llorca, Boussiron, Schwan, Facy, Reynaud (bib32) 2003; 27 Tuppin, de Roquefeuil, Weill, Ricordeau, Merlière (bib46) 2010; 58 Bongue, Laroche, Gutton, Colvez, Guéguen, Moulin, Merle (bib9) 2011; 67 de Beaurepaire (bib19) 2012; 3 Liu, Wang (bib29) 2013 Greene (bib26) 1992; 15 Nasti, Brakoulias (bib35) 2011; 45 Comité Technique de Pharmacovigilance de mars 2012. Effets indésirables du baclofène dans le traitement des addictions. Suivi national de pharmacovigilance: année 2011. Rumpf, Hapke, Meyer, John (bib40) 2002; 37 Journal Officiel de la République Française. Arrêté du 11 juillet 2012 relatif à la mise en oeuvre du système national d'information interrégimes de l'assurance maladie. Shorter, Kosten (bib42) 2011; 9 Blin, Lassalle, Dureau-Pournin, Ambrosino, Bernard, Abouelfath, Gin, Le Jeunne, Pariente, Droz, Moore (bib8) 2012; 55 Rolland, Deheul, Danel, Bordet, Cottencin (bib39) 2010; 65 Smith, LaRocca, Giesser, Scheinberg (bib43) 1991; 41 Tiffany, Wray (bib45) 2012; 1248 Pariente, Pinet, Moride, Merlière, Moore, Fourrier-Réglat (bib37) 2010; 19 Muzyk, Rivelli, Gagliardi (bib34) 2012; 26 Evans, Bisaga (bib22) 2009; 33 Frauger, Pauly, Pradel, Rouby, Arditti, Thirion, Lapeyre-Mestre, Micallef (bib24) 2011; 25 Charrel, Cuervo-Lombard, Miron, Fruntes, Béra-Potelle, Limosin (bib11) 2010; 19 Addolorato, Leggio, Ferrulli, Cardone, Bedogni, Caputo, Gasbarrini, Landolfi (bib3) 2011; 46 Lapeyre-Mestre, M., Palmaro, A, 2011. Comparison of Utilization Data of Psychoactive Medications Having an Abuse Potential in the Different European Countries. Centre d′Evaluation et d′Information sur la Pharmacodépendence–Addictovigilance (CEIP-A). Available on specific request to the authors. Ameisen (bib6) 2008 Leung, Whyte, Isbister (bib28) 2006; 18 ClinicalTrials.gov-a. Baclofen for the Treatment of Alcohol Drinkers. Soufia, Plaze, Gueguen, Demigneux, Olié, Gaillard (bib44) 2010; 30 Addolorato, Leggio, Abenavoli, Agabio, Caputo, Capristo, Colombo, Gessa, Gasbarrini (bib2) 2006; 119 Lyon, Khan, Gessert, Larson, Renier (bib30) 2011; 6 Colombo, Addolorato, Agabio, Carai, Pibiri, Serra, Vacca, Gessa (bib14) 2004; 6 Colombo, Agabio, Carai, Lobina, Pani, Reali, Addolorato, Gessa (bib15) 2000; 24 Addolorato (10.1016/j.euroneuro.2013.09.008_bib4) 2007; 370 Ameisen (10.1016/j.euroneuro.2013.09.008_bib5) 2005; 40 Saddichha (10.1016/j.euroneuro.2013.09.008_bib41) 2011; 51 Soufia (10.1016/j.euroneuro.2013.09.008_bib44) 2010; 30 Malet (10.1016/j.euroneuro.2013.09.008_bib32) 2003; 27 Greene (10.1016/j.euroneuro.2013.09.008_bib26) 1992; 15 Garbutt (10.1016/j.euroneuro.2013.09.008_bib25) 2010; 34 Charrel (10.1016/j.euroneuro.2013.09.008_bib11) 2010; 19 Braillon (10.1016/j.euroneuro.2013.09.008_bib10) 2012; 47 Shorter (10.1016/j.euroneuro.2013.09.008_bib42) 2011; 9 Colombo (10.1016/j.euroneuro.2013.09.008_bib15) 2000; 24 10.1016/j.euroneuro.2013.09.008_bib17 Evans (10.1016/j.euroneuro.2013.09.008_bib22) 2009; 33 Smith (10.1016/j.euroneuro.2013.09.008_bib43) 1991; 41 Beck (10.1016/j.euroneuro.2013.09.008_bib7) 2011; 59 Dore (10.1016/j.euroneuro.2013.09.008_bib20) 2011; 46 Addolorato (10.1016/j.euroneuro.2013.09.008_bib1) 2002; 37 10.1016/j.euroneuro.2013.09.008_bib101 Leung (10.1016/j.euroneuro.2013.09.008_bib28) 2006; 18 Colombo (10.1016/j.euroneuro.2013.09.008_bib14) 2004; 6 Muzyk (10.1016/j.euroneuro.2013.09.008_bib34) 2012; 26 Lyon (10.1016/j.euroneuro.2013.09.008_bib30) 2011; 6 Macaigne (10.1016/j.euroneuro.2013.09.008_bib31) 2011; 35 Rolland (10.1016/j.euroneuro.2013.09.008_bib38) 2012; 107 Tiffany (10.1016/j.euroneuro.2013.09.008_bib45) 2012; 1248 Bongue (10.1016/j.euroneuro.2013.09.008_bib9) 2011; 67 Nasti (10.1016/j.euroneuro.2013.09.008_bib35) 2011; 45 Addolorato (10.1016/j.euroneuro.2013.09.008_bib3) 2011; 46 Davidoff (10.1016/j.euroneuro.2013.09.008_bib18) 1985; 17 Effertz (10.1016/j.euroneuro.2013.09.008_bib21) 2013; 23 Fournier (10.1016/j.euroneuro.2013.09.008_bib23) 2012; 21 Liu (10.1016/j.euroneuro.2013.09.008_bib29) 2013 10.1016/j.euroneuro.2013.09.008_bib27 Frauger (10.1016/j.euroneuro.2013.09.008_bib24) 2011; 25 Ameisen (10.1016/j.euroneuro.2013.09.008_bib6) 2008 10.1016/j.euroneuro.2013.09.008_bib13 Wittchen (10.1016/j.euroneuro.2013.09.008_bib47) 2011; 21 10.1016/j.euroneuro.2013.09.008_bib12 de Beaurepaire (10.1016/j.euroneuro.2013.09.008_bib19) 2012; 3 Colombo (10.1016/j.euroneuro.2013.09.008_bib16) 2003; 70 Malet (10.1016/j.euroneuro.2013.09.008_bib33) 2009; 36 Addolorato (10.1016/j.euroneuro.2013.09.008_bib2) 2006; 119 Rolland (10.1016/j.euroneuro.2013.09.008_bib39) 2010; 65 Tuppin (10.1016/j.euroneuro.2013.09.008_bib46) 2010; 58 Noize (10.1016/j.euroneuro.2013.09.008_bib36) 2009; 18 Pariente (10.1016/j.euroneuro.2013.09.008_bib37) 2010; 19 Rumpf (10.1016/j.euroneuro.2013.09.008_bib40) 2002; 37 Blin (10.1016/j.euroneuro.2013.09.008_bib8) 2012; 55 |
| References_xml | – volume: 65 start-page: 511 year: 2010 end-page: 518 ident: bib39 article-title: [A system of prescriptions without drug approval: example of baclofen.] publication-title: Therapie – volume: 59 start-page: 285 year: 2011 end-page: 294 ident: bib7 article-title: Increasing trends in screening for addictives behaviors among general practitioners in France publication-title: Revue d'Epidémiologie et de Santé Publique – volume: 19 start-page: 343 year: 2010 end-page: 348 ident: bib11 article-title: Alcohol dependence in women: difficulty of its assessment in general practice publication-title: Journal of Women's Health (Larchmt) – year: 2008 ident: bib6 article-title: Le Dernier Verre – volume: 21 start-page: 343 year: 2012 end-page: 351 ident: bib23 article-title: Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France publication-title: Pharmacoepidemiology and Drug Safety – volume: 23 start-page: 742 year: 2013 end-page: 748 ident: bib21 article-title: The burden and cost of disorders of the brain in Europe with the inclusion of harmful alcohol use and nicotine addiction publication-title: European Neuropsychopharmacology – volume: 30 start-page: 759 year: 2010 end-page: 760 ident: bib44 article-title: Behavioral disinhibition with baclofen publication-title: Journal of Clinical Psychopharmacology – volume: 15 start-page: 276 year: 1992 end-page: 288 ident: bib26 article-title: Baclofen in the treatment of dystonia publication-title: Clinical Neuropharmacology – volume: 27 start-page: 61 year: 2003 end-page: 66 ident: bib32 article-title: General practitioners and alcohol use disorders: quantity without quality publication-title: Alcoholism: Clinical and Experimental Research – volume: 26 start-page: 69 year: 2012 end-page: 78 ident: bib34 article-title: Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence publication-title: CNS Drugs – volume: 24 start-page: 58 year: 2000 end-page: 66 ident: bib15 article-title: Ability of baclofen in reducing alcohol intake and withdrawal severity: I—Preclinical evidence publication-title: Alcoholism: Clinical and Experimental Research – volume: 18 start-page: 310 year: 2009 end-page: 319 ident: bib36 article-title: Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study publication-title: Pharmacoepidemiology and Drug Safety – volume: 36 start-page: 457 year: 2009 end-page: 462 ident: bib33 article-title: Outcomes from primary care management of alcohol dependence in France publication-title: Journal of Substance Abuse Treatment – volume: 34 start-page: 1849 year: 2010 end-page: 1857 ident: bib25 article-title: Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial publication-title: Alcoholism: Clinical and Experimental Research – volume: 19 start-page: 680 year: 2010 end-page: 686 ident: bib37 article-title: Factors associated with persistence of cholinesterase inhibitor treatments in the elderly publication-title: Pharmacoepidemiology and Drug Safety – reference: Journal Officiel de la République Française. Arrêté du 11 juillet 2012 relatif à la mise en oeuvre du système national d'information interrégimes de l'assurance maladie. < – volume: 45 start-page: 86 year: 2011 end-page: 87 ident: bib35 article-title: Chronic baclofen abuse and withdrawal delirium publication-title: Australian and New Zealand Journal of Psychiatry – volume: 370 start-page: 1915 year: 2007 end-page: 1922 ident: bib4 article-title: Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study publication-title: Lancet – volume: 67 start-page: 1291 year: 2011 end-page: 1299 ident: bib9 article-title: Potentially inappropriate drug prescription in the elderly in France: a population-based study from the French National Insurance Healthcare system publication-title: European Journal of Clinical Pharmacology – volume: 107 start-page: 848 year: 2012 end-page: 849 ident: bib38 article-title: Alcohol-dependence: the current French craze for baclofen publication-title: Addiction – reference: Lapeyre-Mestre, M., Palmaro, A, 2011. Comparison of Utilization Data of Psychoactive Medications Having an Abuse Potential in the Different European Countries. Centre d′Evaluation et d′Information sur la Pharmacodépendence–Addictovigilance (CEIP-A). Available on specific request to the authors. – volume: 17 start-page: 107 year: 1985 end-page: 116 ident: bib18 article-title: Antispasticity drugs: mechanisms of action publication-title: Annals of Neurology – volume: 33 start-page: 19 year: 2009 end-page: 30 ident: bib22 article-title: Acute interaction of baclofen in combination with alcohol in heavy social drinkers publication-title: Alcoholism: Clinical and Experimental Research – reference: ClinicalTrials.gov-a. Baclofen for the Treatment of Alcohol Drinkers. – volume: 6 start-page: 469 year: 2011 end-page: 474 ident: bib30 article-title: Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial publication-title: Journal of Hospital Medicine – volume: 35 start-page: 420 year: 2011 end-page: 421 ident: bib31 article-title: Baclofen-induced acute hepatitis in alcohol-dependent patient publication-title: Clinics and Research in Hepatology and Gastroenterology – year: 2013 ident: bib29 article-title: Baclofen for alcohol withdrawal publication-title: Cochrane Database of Systematic Reviews – volume: 51 start-page: 1733 year: 2011 end-page: 1734 ident: bib41 article-title: Baclofen-induced morbiliform rashes: a case series publication-title: Journal of Clinical Pharmacology – volume: 46 start-page: 714 year: 2011 end-page: 720 ident: bib20 article-title: Clinical experience with baclofen in the management of alcohol-dependent patients with psychiatric comorbidity: a selected case series publication-title: Alcohol and Alcoholism – reference: ClinicalTrials.gov-b. Efficacy and Safety of Baclofen for Maintenance of Abstinence in Alcohol Dependent Patients. – volume: 55 start-page: 644 year: 2012 end-page: 653 ident: bib8 article-title: Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database publication-title: Diabetologia – volume: 25 start-page: 633 year: 2011 end-page: 641 ident: bib24 article-title: Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network publication-title: Fundamental and Clinical Pharmacology – volume: 47 start-page: 631 year: 2012 end-page: 632 ident: bib10 article-title: Baclofen and protecting the patients during research publication-title: Alcohol and Alcoholism – volume: 70 start-page: 105 year: 2003 end-page: 108 ident: bib16 article-title: Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats publication-title: Drug Alcohol Depend – volume: 58 start-page: 286 year: 2010 end-page: 290 ident: bib46 article-title: French national health insurance information system and the permanent beneficiaries sample publication-title: Revue d'Epidémiologie et de Santé Publique – volume: 1248 start-page: 1 year: 2012 end-page: 17 ident: bib45 article-title: The clinical significance of drug craving publication-title: Annals of the New York Academy of Sciences – volume: 41 start-page: 1829 year: 1991 end-page: 1831 ident: bib43 article-title: High-dose oral baclofen: experience in patients with multiple sclerosis publication-title: Neurology – volume: 37 start-page: 504 year: 2002 end-page: 508 ident: bib1 article-title: Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study publication-title: Alcohol and Alcoholism – volume: 9 start-page: 119 year: 2011 ident: bib42 article-title: Novel pharmacotherapeutic treatments for cocaine addiction publication-title: BMC Medicine – volume: 3 start-page: 103 year: 2012 ident: bib19 article-title: Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients publication-title: Frontiers in Psychiatry – volume: 37 start-page: 261 year: 2002 end-page: 268 ident: bib40 article-title: Screening for alcohol use disorders and at-risk drinking in the general population: psychometric performance of three questionnaires publication-title: Alcohol and Alcoholism – volume: 18 start-page: 77 year: 2006 end-page: 82 ident: bib28 article-title: Baclofen overdose: defining the spectrum of toxicity publication-title: Emergency Medicine Australasia – volume: 119 start-page: 276.e13 year: 2006 end-page: 276.e18 ident: bib2 article-title: Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam publication-title: American Journal of Medicine – volume: 46 start-page: 312 year: 2011 end-page: 317 ident: bib3 article-title: Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial publication-title: Alcohol and Alcoholism – reference: . – volume: 6 start-page: 403 year: 2004 end-page: 414 ident: bib14 article-title: Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics publication-title: Neurotoxicity Research – volume: 21 start-page: 655 year: 2011 end-page: 679 ident: bib47 article-title: The size and burden of mental disorders and other disorders of the brain in Europe 2010 publication-title: European Neuropsychopharmacology – reference: Comité Technique de Pharmacovigilance de mars 2012. Effets indésirables du baclofène dans le traitement des addictions. Suivi national de pharmacovigilance: année 2011. – volume: 40 start-page: 147 year: 2005 end-page: 150 ident: bib5 article-title: Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician publication-title: Alcohol and Alcoholism – volume: 9 start-page: 119 year: 2011 ident: 10.1016/j.euroneuro.2013.09.008_bib42 article-title: Novel pharmacotherapeutic treatments for cocaine addiction publication-title: BMC Medicine doi: 10.1186/1741-7015-9-119 – volume: 21 start-page: 655 year: 2011 ident: 10.1016/j.euroneuro.2013.09.008_bib47 article-title: The size and burden of mental disorders and other disorders of the brain in Europe 2010 publication-title: European Neuropsychopharmacology doi: 10.1016/j.euroneuro.2011.07.018 – volume: 47 start-page: 631 year: 2012 ident: 10.1016/j.euroneuro.2013.09.008_bib10 article-title: Baclofen and protecting the patients during research publication-title: Alcohol and Alcoholism doi: 10.1093/alcalc/ags060 – volume: 40 start-page: 147 year: 2005 ident: 10.1016/j.euroneuro.2013.09.008_bib5 article-title: Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician publication-title: Alcohol and Alcoholism doi: 10.1093/alcalc/agh130 – volume: 18 start-page: 310 year: 2009 ident: 10.1016/j.euroneuro.2013.09.008_bib36 article-title: Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study publication-title: Pharmacoepidemiology and Drug Safety doi: 10.1002/pds.1717 – volume: 3 start-page: 103 year: 2012 ident: 10.1016/j.euroneuro.2013.09.008_bib19 article-title: Suppression of alcohol dependence using baclofen: a 2-year observational study of 100 patients publication-title: Frontiers in Psychiatry doi: 10.3389/fpsyt.2012.00103 – ident: 10.1016/j.euroneuro.2013.09.008_bib13 – volume: 36 start-page: 457 year: 2009 ident: 10.1016/j.euroneuro.2013.09.008_bib33 article-title: Outcomes from primary care management of alcohol dependence in France publication-title: Journal of Substance Abuse Treatment doi: 10.1016/j.jsat.2008.08.006 – volume: 27 start-page: 61 year: 2003 ident: 10.1016/j.euroneuro.2013.09.008_bib32 article-title: General practitioners and alcohol use disorders: quantity without quality publication-title: Alcoholism: Clinical and Experimental Research doi: 10.1111/j.1530-0277.2003.tb02722.x – volume: 6 start-page: 403 year: 2004 ident: 10.1016/j.euroneuro.2013.09.008_bib14 article-title: Role of GABA(B) receptor in alcohol dependence: reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics publication-title: Neurotoxicity Research doi: 10.1007/BF03033315 – volume: 18 start-page: 77 year: 2006 ident: 10.1016/j.euroneuro.2013.09.008_bib28 article-title: Baclofen overdose: defining the spectrum of toxicity publication-title: Emergency Medicine Australasia doi: 10.1111/j.1742-6723.2006.00805.x – volume: 70 start-page: 105 year: 2003 ident: 10.1016/j.euroneuro.2013.09.008_bib16 article-title: Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats publication-title: Drug Alcohol Depend doi: 10.1016/S0376-8716(02)00333-2 – volume: 26 start-page: 69 year: 2012 ident: 10.1016/j.euroneuro.2013.09.008_bib34 article-title: Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence publication-title: CNS Drugs doi: 10.2165/11597320-000000000-00000 – volume: 17 start-page: 107 year: 1985 ident: 10.1016/j.euroneuro.2013.09.008_bib18 article-title: Antispasticity drugs: mechanisms of action publication-title: Annals of Neurology doi: 10.1002/ana.410170202 – volume: 55 start-page: 644 year: 2012 ident: 10.1016/j.euroneuro.2013.09.008_bib8 article-title: Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database publication-title: Diabetologia doi: 10.1007/s00125-011-2429-5 – volume: 37 start-page: 261 year: 2002 ident: 10.1016/j.euroneuro.2013.09.008_bib40 article-title: Screening for alcohol use disorders and at-risk drinking in the general population: psychometric performance of three questionnaires publication-title: Alcohol and Alcoholism doi: 10.1093/alcalc/37.3.261 – volume: 34 start-page: 1849 year: 2010 ident: 10.1016/j.euroneuro.2013.09.008_bib25 article-title: Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial publication-title: Alcoholism: Clinical and Experimental Research doi: 10.1111/j.1530-0277.2010.01273.x – volume: 21 start-page: 343 year: 2012 ident: 10.1016/j.euroneuro.2013.09.008_bib23 article-title: Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France publication-title: Pharmacoepidemiology and Drug Safety doi: 10.1002/pds.3213 – volume: 30 start-page: 759 year: 2010 ident: 10.1016/j.euroneuro.2013.09.008_bib44 article-title: Behavioral disinhibition with baclofen publication-title: Journal of Clinical Psychopharmacology doi: 10.1097/JCP.0b013e3181fb7b97 – volume: 370 start-page: 1915 year: 2007 ident: 10.1016/j.euroneuro.2013.09.008_bib4 article-title: Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study publication-title: Lancet doi: 10.1016/S0140-6736(07)61814-5 – volume: 51 start-page: 1733 year: 2011 ident: 10.1016/j.euroneuro.2013.09.008_bib41 article-title: Baclofen-induced morbiliform rashes: a case series publication-title: Journal of Clinical Pharmacology doi: 10.1177/0091270010385936 – volume: 65 start-page: 511 year: 2010 ident: 10.1016/j.euroneuro.2013.09.008_bib39 article-title: [A system of prescriptions without drug approval: example of baclofen.] publication-title: Therapie doi: 10.2515/therapie/2010073 – volume: 46 start-page: 312 year: 2011 ident: 10.1016/j.euroneuro.2013.09.008_bib3 article-title: Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial publication-title: Alcohol and Alcoholism doi: 10.1093/alcalc/agr017 – ident: 10.1016/j.euroneuro.2013.09.008_bib101 – volume: 35 start-page: 420 year: 2011 ident: 10.1016/j.euroneuro.2013.09.008_bib31 article-title: Baclofen-induced acute hepatitis in alcohol-dependent patient publication-title: Clinics and Research in Hepatology and Gastroenterology doi: 10.1016/j.clinre.2011.01.019 – volume: 67 start-page: 1291 year: 2011 ident: 10.1016/j.euroneuro.2013.09.008_bib9 article-title: Potentially inappropriate drug prescription in the elderly in France: a population-based study from the French National Insurance Healthcare system publication-title: European Journal of Clinical Pharmacology doi: 10.1007/s00228-011-1077-5 – volume: 23 start-page: 742 year: 2013 ident: 10.1016/j.euroneuro.2013.09.008_bib21 article-title: The burden and cost of disorders of the brain in Europe with the inclusion of harmful alcohol use and nicotine addiction publication-title: European Neuropsychopharmacology doi: 10.1016/j.euroneuro.2012.07.010 – year: 2013 ident: 10.1016/j.euroneuro.2013.09.008_bib29 article-title: Baclofen for alcohol withdrawal publication-title: Cochrane Database of Systematic Reviews doi: 10.1002/14651858.CD008502.pub3 – volume: 1248 start-page: 1 year: 2012 ident: 10.1016/j.euroneuro.2013.09.008_bib45 article-title: The clinical significance of drug craving publication-title: Annals of the New York Academy of Sciences doi: 10.1111/j.1749-6632.2011.06298.x – volume: 107 start-page: 848 year: 2012 ident: 10.1016/j.euroneuro.2013.09.008_bib38 article-title: Alcohol-dependence: the current French craze for baclofen publication-title: Addiction doi: 10.1111/j.1360-0443.2011.03752.x – volume: 59 start-page: 285 year: 2011 ident: 10.1016/j.euroneuro.2013.09.008_bib7 article-title: Increasing trends in screening for addictives behaviors among general practitioners in France publication-title: Revue d'Epidémiologie et de Santé Publique doi: 10.1016/j.respe.2011.03.059 – ident: 10.1016/j.euroneuro.2013.09.008_bib12 – volume: 15 start-page: 276 year: 1992 ident: 10.1016/j.euroneuro.2013.09.008_bib26 article-title: Baclofen in the treatment of dystonia publication-title: Clinical Neuropharmacology doi: 10.1097/00002826-199208000-00002 – volume: 24 start-page: 58 year: 2000 ident: 10.1016/j.euroneuro.2013.09.008_bib15 article-title: Ability of baclofen in reducing alcohol intake and withdrawal severity: I—Preclinical evidence publication-title: Alcoholism: Clinical and Experimental Research – volume: 58 start-page: 286 year: 2010 ident: 10.1016/j.euroneuro.2013.09.008_bib46 article-title: French national health insurance information system and the permanent beneficiaries sample publication-title: Revue d'Epidémiologie et de Santé Publique doi: 10.1016/j.respe.2010.04.005 – ident: 10.1016/j.euroneuro.2013.09.008_bib17 – volume: 19 start-page: 680 year: 2010 ident: 10.1016/j.euroneuro.2013.09.008_bib37 article-title: Factors associated with persistence of cholinesterase inhibitor treatments in the elderly publication-title: Pharmacoepidemiology and Drug Safety doi: 10.1002/pds.1933 – volume: 25 start-page: 633 year: 2011 ident: 10.1016/j.euroneuro.2013.09.008_bib24 article-title: Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network publication-title: Fundamental and Clinical Pharmacology doi: 10.1111/j.1472-8206.2010.00882.x – volume: 46 start-page: 714 year: 2011 ident: 10.1016/j.euroneuro.2013.09.008_bib20 article-title: Clinical experience with baclofen in the management of alcohol-dependent patients with psychiatric comorbidity: a selected case series publication-title: Alcohol and Alcoholism doi: 10.1093/alcalc/agr131 – volume: 41 start-page: 1829 year: 1991 ident: 10.1016/j.euroneuro.2013.09.008_bib43 article-title: High-dose oral baclofen: experience in patients with multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.41.11.1829 – volume: 37 start-page: 504 year: 2002 ident: 10.1016/j.euroneuro.2013.09.008_bib1 article-title: Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study publication-title: Alcohol and Alcoholism doi: 10.1093/alcalc/37.5.504 – volume: 33 start-page: 19 year: 2009 ident: 10.1016/j.euroneuro.2013.09.008_bib22 article-title: Acute interaction of baclofen in combination with alcohol in heavy social drinkers publication-title: Alcoholism: Clinical and Experimental Research doi: 10.1111/j.1530-0277.2008.00805.x – volume: 6 start-page: 469 year: 2011 ident: 10.1016/j.euroneuro.2013.09.008_bib30 article-title: Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial publication-title: Journal of Hospital Medicine doi: 10.1002/jhm.928 – volume: 119 start-page: 276.e13 year: 2006 ident: 10.1016/j.euroneuro.2013.09.008_bib2 article-title: Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam publication-title: American Journal of Medicine doi: 10.1016/j.amjmed.2005.08.042 – volume: 19 start-page: 343 year: 2010 ident: 10.1016/j.euroneuro.2013.09.008_bib11 article-title: Alcohol dependence in women: difficulty of its assessment in general practice publication-title: Journal of Women's Health (Larchmt) doi: 10.1089/jwh.2009.1505 – volume: 45 start-page: 86 year: 2011 ident: 10.1016/j.euroneuro.2013.09.008_bib35 article-title: Chronic baclofen abuse and withdrawal delirium publication-title: Australian and New Zealand Journal of Psychiatry doi: 10.3109/00048674.2010.524622 – ident: 10.1016/j.euroneuro.2013.09.008_bib27 – year: 2008 ident: 10.1016/j.euroneuro.2013.09.008_bib6 |
| SSID | ssj0015339 |
| Score | 2.2642057 |
| Snippet | Recently, baclofen has been widely promoted for treatment of alcohol dependence in France. Our aim was firstly to describe the incidence of patients newly... Abstract Recently, baclofen has been widely promoted for treatment of alcohol dependence in France. Our aim was firstly to describe the incidence of patients... |
| SourceID | hal proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 192 |
| SubjectTerms | Addictive behavior Alcoholism Alcoholism - complications Alcoholism - drug therapy Alcoholism - epidemiology Alcoholism / complications Alcoholism / drug therapy Alcoholism / epidemiology Baclofen / administration & dosage Baclofen / therapeutic use Dantrolene / therapeutic use Europe Female France / epidemiology Hospitalization Humans Incidence Male Middle Aged Muscle Relaxants, Central / administration & dosage Muscle Relaxants, Central / therapeutic use Nervous System Diseases / complications Nervous System Diseases / drug therapy Nervous System Diseases / epidemiology Nervous System Diseases / therapy Practice Patterns, Physicians' / statistics & numerical data Practice Patterns, Physicians' / trends Retrospective Studies Time Factors Baclofen Baclofen - administration & dosage Baclofen - therapeutic use Cohort studies Dantrolene - therapeutic use Europe Female France - epidemiology General practitioners Hospitalization Human health and pathology Humans Incidence Internal Medicine Life Sciences Male Middle Aged Muscle Relaxants, Central - administration & dosage Muscle Relaxants, Central - therapeutic use Nervous System Diseases - complications Nervous System Diseases - drug therapy Nervous System Diseases - epidemiology Nervous System Diseases - therapy Practice Patterns, Physicians' - statistics & numerical data Practice Patterns, Physicians' - trends Psychiatry Retrospective Studies Time Factors |
| Title | Baclofen for alcohol dependence in France: Incidence of treated patients and prescription patterns—A cohort study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0924977X13002745 https://www.clinicalkey.es/playcontent/1-s2.0-S0924977X13002745 https://dx.doi.org/10.1016/j.euroneuro.2013.09.008 https://www.ncbi.nlm.nih.gov/pubmed/24139234 https://www.proquest.com/docview/1494303808 https://www.proquest.com/docview/1516744733 https://hal.science/hal-03526189 |
| Volume | 24 |
| WOSCitedRecordID | wos000331680100002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1873-7862 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0015339 issn: 0924-977X databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZ24YEXxJ1ymQxCexmR0txs723ApjFVoxId6puVOLboNNLStNP2z_h5nBPbSYFNGw-8RJUV20m-r8fn2OdCyFtueMEzDUaOKYogyQ0LisLwwJRZpvpZpFRTpvPrgB0f8_FYDNfWfvpYmPMzVlX84kLM_ivU0AZgY-jsP8DdDgoN8BtAhyvADtdbAf8-V2dTo60DYW4r4O74WreqyRHSVNNogtJxp902o68AKpCggLpcq7VPItBJllmTjbOqgyDfwYHni5X8tH_u7zepMm2U16xLkN1u4X9czqbLSx-jrbvlEN5xYol0BMMEw7xWeesHAgp0Xp0uG_bhIT8X3ycrvbEcTO5Cd2B259nrdjX6iXeEbgUxZ3HAuJPU-oo2J71tBLZjabQiivu2xt5fS4TdrTjFvJrT5kOgf1_cJLsNebcqek-A48_y4GQwkKP98Wh79iPAemV4ru-Kt6yTzYilApaEzb1P--Oj9gQL1Gg0vdpn_s238Mq5r9OM1r-hi-519k-jB43uk3vOgKF7lngPyJquHpLtoQX48h0ddQF99Tu6TYcr0D8ic89OCuykjp20YyedVNSyc5e23KRTQx03qecmBW7SVW7SFW5Sy03acPMxOTnYH304DFzZj0CliVgEwqgsYtzkUZaC-gj6vAm1ieNQGJEq9NtSoKbyUvMsLRLDyqLI8qwwscl4qYoifkI2Kvi8zwiNUx2WQrE41iIpylJkUSjKiJdlqsEQSXok859cKpcTH0uznEnv_HgqW6wkYiVDIQGrHgnbjjObFubmLtxjKn3UM6zTEnh5c1d2VVddO7FTy76sIxnKLyFupzA2xkPqiCVpj-y2PZ1KbVXl2037BqjXvh8moj_cG0hswyzKWZ-L836PvPbMlLAy4XFjXunpEp4pwdIOMceBrr0nxSioBADqkaeW1u18eOIP5mfy_BYzvCB3Oynykmws5kv9itxR54tJPd8i62zMt9w_9Be50yMC |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Baclofen+for+alcohol+dependence+in+France%3A+incidence+of+treated+patients+and+prescription+patterns--a+cohort+study&rft.jtitle=European+neuropsychopharmacology&rft.au=Dupouy%2C+Julie&rft.au=Fournier%2C+Jean-Pascal&rft.au=Jouanjus%2C+%C3%89milie&rft.au=Palmaro%2C+Aurore&rft.date=2014-02-01&rft.issn=1873-7862&rft.eissn=1873-7862&rft.volume=24&rft.issue=2&rft.spage=192&rft_id=info:doi/10.1016%2Fj.euroneuro.2013.09.008&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0924977X%2FS0924977X14X00027%2Fcov150h.gif |